author-photo

Tobias Neff

Janssen Pharmaceutica

5

Papers

67

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

2021 Advances in Therapy
Show All
- Source
- Cite
- Save
Citations (2)
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

2020 Leukemia
Show All
- Source
- Cite
- Save
Citations (30)
Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

2018 Blood
Show All
- Source
- Cite
- Save
Citations (7)